Jeungpyung Health Center, Jeungpyung-gun, Chungbuk, 368-900, Korea.
Asian J Androl. 2011 Nov;13(6):846-50. doi: 10.1038/aja.2011.25. Epub 2011 Jul 25.
This study was undertaken to determine the impact on ejaculatory function of tamsulosin (0.2 mg) given once daily (OD) for 12 weeks and to identify risk factors for ejaculatory dysfunction in patients undergoing this treatment. Males with an International Prostatic Symptom Score (IPSS) ≥8 were enrolled in this study. All participants completed questionnaires, including the IPSS and the Male Sexual Health Questionnaire (MSHQ), and serum prostate-specific antigen, transrectal ultrasound and uroflowmetry with post-void residual were measured. After initiating 0.2 mg OD tamsulosin, patients were re-evaluated on the fourth and twelfth weeks of medication. The chi-squared test, the independent t-test and one-way ANOVA were used to compare means. Binary logistic regression analysis was used to calculate the odds ratio for all risk factors. A total of 177 men constituted the study cohort. No significant difference was observed between baseline and follow-up for the erectile function, ejaculatory function, satisfaction, sexual activity and desire domains (EFD, EjFD, SDA and ADD) or for erectile or ejaculatory bother mean scores. After 12 weeks, the overall incidence of ejaculatory dysfunction (EjD) was 13.4%. Incidences of the seven different types of EjD (decreased frequency, delay, dryness, decreased strength/force, decreased volume, decreased pleasure and pain at ejaculation) were 2.4%, 3.1%, 3.9%, 3.9%, 6.3%, 7.1% and 3.1%, respectively. Baseline EjFD scores were higher for IPSS responders than for non-responders (26.09 vs. 24.06, P=0.03). An EjFD score reduction was more frequent in IPSS responders. The incidence of EjD was small, but not negligible and was more frequent in patients with less lower urinary tract symptoms, a smaller prostate, higher baseline MSHQ totals and higher EjFD scores.
这项研究旨在确定坦索罗辛（0.2 毫克）每日一次（OD）治疗 12 周对射精功能的影响，并确定接受这种治疗的患者发生射精功能障碍的风险因素。国际前列腺症状评分（IPSS）≥8 的男性参与了这项研究。所有参与者都完成了问卷，包括 IPSS 和男性性健康问卷（MSHQ），并测量了血清前列腺特异性抗原、经直肠超声和尿流率以及残余尿量。开始 0.2 毫克 OD 坦索罗辛后，患者在用药的第四周和第十二周进行重新评估。卡方检验、独立 t 检验和单因素方差分析用于比较均值。二元逻辑回归分析用于计算所有风险因素的优势比。共有 177 名男性构成了研究队列。在勃起功能、射精功能、满意度、性活动和欲望领域（EFD、EjFD、SDA 和 ADD）或勃起或射精困扰的平均评分方面，基线和随访之间没有观察到显著差异。12 周后，射精功能障碍（EjD）的总发生率为 13.4%。七种不同类型的 EjD（频率降低、延迟、干燥、强度/力降低、量减少、快感降低和射精时疼痛）的发生率分别为 2.4%、3.1%、3.9%、3.9%、6.3%、7.1%和 3.1%。IPSS 应答者的基线 EjFD 评分高于非应答者（26.09 比 24.06，P=0.03）。IPSS 应答者的 EjFD 评分降低更为频繁。EjD 的发生率较小，但不容忽视，在有较少下尿路症状、较小前列腺、较高基线 MSHQ 总分和较高 EjFD 评分的患者中更为常见。
